ReviewEuropean respiratory review : an official journal of the European Respiratory Society2026
Geriatric respiratory medicine 2026: from artificial intelligence to personalised management of the multimorbid patient.
Review in European respiratory review : an official journal of the European Respiratory Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The profound demographic shift toward an ageing population has decisively moved the burden of chronic and acute lung diseases towards older adults, necessitating a transition from organ-centred models to integrated, multidimensional care. This review outlines a pragmatic framework for managing the complex interplay of immunosenescence, frailty and multimorbidity. In acute care, "pneumonia-associated sarcopenia" is identified as a critical driver of recurrent infections and functional decline, requiring a shift towards aspiration prevention and the aid of diagnostic tools such as lung ultrasound. The selection of noninvasive respiratory support, including high-flow nasal cannulas and noninvasive ventilation, must balance physiological efficacy with the risks of delirium and patient self-inflicted lung injury. Preventive strategies have evolved with the introduction of 20-valent pneumococcal and respiratory syncytial virus vaccines, alongside proactive screening for ɑ1-antitrypsin deficiency to enable precision interventions. Chronic disease management emphasises a "device-centric" inhalation therapy approach, tailoring delivery systems to impaired peak inspiratory flows and cognitive status rather than to pharmacology alone. The advent of biological therapies, particularly the use of dupilumab and mepolizumab in eosinophilic COPD, offers a transformative "steroid-sparing" effect, aiming for clinical stability and preserved independence. Finally, the integration of artificial intelligence as "augmented intelligence" and the "4Ms" multidisciplinary model (mentation, medication, mobility, morbidities) provide the necessary tools to navigate clinical complexity. This holistic strategy ensures that technological innovation remains anchored in patient-centred goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.